Trial intelligence / Profile preview

MenACWY-TT long-term persistence and booster study in toddlers and children

2012-002719-24Phase 2

Sponsor
GSK
Start
Jun 2015
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

Phase 2, open-label trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine in meningococcal disease (2 cohorts), sponsored by GSK. Primary endpoint: Meningococcal hSBA antibody titers.

02

Drugs

meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine
03

Conditions

meningococcal disease

Beyond the preview

Go deeper on 2012-002719-24.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-002719-24.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call